3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Withdrawn
1
Sponsor Class
OTHER
1
Study Type
Observational
1
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Leukemia, Myeloid, Acute
3102
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2086
Leukemia
2013
Leukemia, Lymphocytic, Chronic, B-Cell
1771
Myelodysplastic Syndromes
1298
Hematologic Neoplasms
1067
Lymphoma
1029
Lymphoma, Non-Hodgkin
981
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
713
Lymphoma, Follicular
704
Lymphoma, Mantle-Cell
678
Lymphoma, Large B-Cell, Diffuse
657
Burkitt Lymphoma
642
Multiple Myeloma
639
Lymphoma, B-Cell, Marginal Zone
599
Recurrence
587
Hodgkin Disease
575
Leukemia, Myelomonocytic, Chronic
495
Lymphoma, Large-Cell, Immunoblastic
419
Neoplasms
402
Myeloproliferative Disorders
402
Leukemia, Myeloid, Chronic-Phase
391
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
382
Congenital Abnormalities
357
Waldenstrom Macroglobulinemia
330
Blast Crisis
324
Leukemia, Myeloid, Accelerated Phase
290
Lymphoma, T-Cell, Cutaneous
280
Primary Myelofibrosis
270
Anemia, Refractory, with Excess of Blasts
251
Interventions
ogalvibart
1
crexavibart
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Purpura, Thrombotic Thrombocytopenic
×
Other hematologic neoplasm
×
Clear all
NCT05393999
2023-04-24
SABRE
Imperial College Healthcare NHS Trust
Phase 2
Withdrawn